No Intervention: Observational Cohort
OtherNo study-specific intervention is assigned. Participants receive usual clinical care as determined by the treating team
NCT Number: NCT07414160
Nutritional support therapy is a crucial part of ICU patient care, as both malnutrition and overnutrition can lead to adverse clinical outcomes. Meticulous monitoring of nutritional support is essential. Unfortunately, to date, there are no biomarkers available to assess the appropriateness of nutritional support in the ICU setting. However, mounting evidence suggests that phenotypic analysis of patients using nutritional biomarkers or risk screening scores for adaptation may enhance our ability to characterize patients in terms of prognosis and likelihood of treatment response.
This study aims to identify the trajectory patterns of prealbumin changes based on dynamic monitoring data of prealbumin during hospitalization of critically ill patients, and to analyze the Association between different trajectory groups and patient prognosis. In addition, this study will further analyze its Association with nutritional intake and nutritional indicators, thereby assessing the potential value of prealbumin change trajectories in terms of the adequacy and effectiveness of nutritional support for critically ill patients.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Elevated prealbumin is a good predictor of positive nitrogen balance. Compared to albumin's half-life of 19-21 days, prealbumin is advantageous in assessing short-term nutritional changes and has been widely recognized as a biomarker for nutritional status and recovery of eating ability. However, prealbumin levels vary considerably depending on patient characteristics, degree of inflammation, and stage of critical illness. In acute inflammation, infection, or trauma, prealbumin concentrations decrease due to various factors, including cytokine-induced downregulation of synthesis, extravasation into the vascular system, blood dilution, and increased consumption. Multiple studies have shown that prealbumin is associated with poor prognosis.
Furthermore, the short half-life of prealbumin means that in the acute phase, PAB levels fluctuate over time. The trajectory of PAB level changes, rather than a single point, may provide a promising approach for dynamically assessing the adequacy and effectiveness of nutritional support in malnourished patients. This could help researchers more accurately describe and understand the heterogeneity and similarities within and between individual patients. Therefore, its dynamic changes may better reflect the severity of the patient's condition and the recovery of nutritional status. Previous studies have shown that for critically ill trauma patients, lower-than-normal total respiratory rate (TTR) levels upon admission are independently associated with poorer prognosis, while increased TTR levels over time are associated with better prognosis. Other studies have indicated that for every unit increase in CRP, TTR decreases by 0.024 units. This means that a 0.024-unit increase in CRP followed by a TTR decrease of more than 1 unit may be due to ineffective nutritional support. However, some researchers argue that prealbumin and the effectiveness of nutritional support are not related to outcome.
Therefore, changes in prealbumin levels in the early stages of critical illness pose a diagnostic challenge in distinguishing between the resolution of inflammation, the adequacy of nutritional support, and the shift towards anabolism.
This is an observational clinical study that will be conducted strictly in accordance with the STROBE guidelines. The first phase will utilize database analysis to track the dynamic trends of prealbumin levels, revealing the relationship between different trajectories and nutritional status and patient prognosis. The second phase will prospectively validate this study using similar patients treated at the Intensive Care Unit of Jilin University First Hospital, aiming to clarify the potential value of prealbumin in nutritional support and prognosis for critically ill patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No study-specific intervention is assigned. Participants receive usual clinical care as determined by the treating team
Time frame: From ICU admission (Day 1) through ICU discharge or death, whichever occurs first (up to 28 days).
Death from any cause occurring during the index ICU stay
Time frame: From ICU admission (Day 1) through hospital discharge or death, whichever occurs first (up to 28 days).
Death from any cause occurring during the index hospitalization.
Time frame: From ICU admission (Day 1) through ICU discharge or death, whichever occurs first (up to 28 days).
New-onset infection occurring during the ICU stay (not present or incubating at ICU admission), diagnosed according to prespecified clinical and/or microbiological criteria.
Time frame: From ICU admission (Day 1) through ICU discharge or death, whichever occurs first (up to 28 days).
Number of days from ICU admission to ICU discharge (or death in ICU), calculated in days.
Time frame: 28 days after ICU admission
Number of days alive and free from invasive mechanical ventilation from ICU admission through Day 28; patients who die before Day 28 are assigned 0 ventilator-free days.
Time frame: From ICU admission (Day 1) through ICU discharge or death, whichever occurs first (up to 28 days).
Vasopressor-free days, defined as the number of days alive and free of vasopressor therapy from ICU admission until ICU discharge; patients who die before ICU discharge are assigned 0 vasopressor-free days.
Time frame: 28 days after ICU admission
Time from ICU admission to death from any cause; participants alive at Day 28 will be censored at Day 28
Time frame: Days 1-14 after ICU admission.
Average daily delivered energy /Protein normalized to body weight (kcal or g/kg/day) from enteral and parenteral nutrition (and other calorie sources if captured) over ICU Days 1-14.
Time frame: During the first 14 days after ICU admission (ICU days 1-14).
Interleukin-6 (IL-6) concentration was measured daily (or as clinically obtained) from ICU Day 1 through Day 14; longitudinal change will be evaluated using repeated-measures analysis across ICU Days 1-14.
Time frame: During the first 14 days after ICU admission (ICU days 1-14).
Albumin was measured daily (or as clinically obtained) from ICU Day 1 through Day 14; longitudinal change will be evaluated using repeated-measures analysis across ICU Days 1-14.
Time frame: During the first 14 days after ICU admission (ICU days 1-14).
CRP was measured daily (or as clinically obtained) from ICU Day 1 through Day 14; longitudinal change will be evaluated using repeated-measures analysis across ICU Days 1-14.
Time frame: During the first 14 days after ICU admission (ICU days 1-14).
lymphocyte count was measured daily (or as clinically obtained) from ICU Day 1 through Day 14; longitudinal change will be evaluated using repeated-measures analysis across ICU Days 1-14.
Time frame: During the first 14 days after ICU admission (ICU days 1-14).
White blood cell count was measured daily (or as clinically obtained) from ICU Day 1 through Day 14; longitudinal change will be evaluated using repeated-measures analysis across ICU Days 1-14.
Time frame: During the first 14 days after ICU admission (ICU days 1-14).
Neutrophil count was measured daily (or as clinically obtained) from ICU Day 1 through Day 14; longitudinal change will be evaluated using repeated-measures analysis across ICU Days 1-14.
Time frame: During the first 14 days after ICU admission (ICU days 1-14).
Creatinine was measured daily (or as clinically obtained) from ICU Day 1 through Day 14; longitudinal change will be evaluated using repeated-measures analysis across ICU Days 1-14.
Time frame: During the first 14 days after ICU admission (ICU days 1-14).
Blood urea nitrogen was measured daily (or as clinically obtained) from ICU Day 1 through Day 14; longitudinal change will be evaluated using repeated-measures analysis across ICU Days 1-14.
Time frame: During the first 14 days after ICU admission (ICU days 1-14).
BUN/prealbumin ratio was measured daily (or as clinically obtained) from ICU Day 1 through Day 14; longitudinal change will be evaluated using repeated-measures analysis across ICU Days 1-14.
Contact information is provided by the study sponsor or research team.
The First Hospital of Jilin University
Other
Association Between Dynamic Prealbumin Trajectories and Prognosis in Critically Ill Patients: A Prospective Observational Study
Acronym: PAB-TRACK
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07691996
Critical Illness, Disease Attributes
View Trial DetailsNCT07343440
Critical Illness, Disease Attributes
Geneva, Switzerland
View Trial DetailsNCT07366021
Bundle Care, Comfort
Antalya, Turkey (Türkiye)
View Trial DetailsNCT03098459
Alzheimer Disease, Alzheimer; Early Onset
Nashville, Tennessee, United States
View Trial Details